Chong Kun Dang collaborator on new Korean registry study of SGLT2, GLP-1 drugs in T2DM heart health

This week brought a single new registry entry tied to Chong Kun Dang Pharmaceutical Corp.

• The study, "Evaluation of Cardioprotective Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Korean Patients With Type 2 Diabetes" (NCT07770737), lists Dongtan Sacred Heart Hospital as lead sponsor with Chong Kun Dang Pharmaceutical Corp. as collaborator, and is not yet recruiting with an estimated September 2026 start.¹ The design's stated enrollment of 100 participants corresponds to the study's prospective arm, in which approximately 100 adults with type 2 diabetes who are starting an SGLT2 inhibitor as part of routine clinical care at Dongtan Sacred Heart Hospital¹ will be enrolled, with approximately 50 participants with stage B heart failure undergoing the same assessments after 6 months.¹ The study's separate retrospective arm draws instead on de-identified electronic health record data mapped to the Observational Medical Outcomes Partnership Common Data Model, obtained from participating Korean hospitals through a distributed data network,¹ a cohort whose size is not specified in the record.